diagnosis
The initial symptoms and signs of non-epithelial ovarian cancers are usually characterized by subacute pelvic pain, feeling of pelvic pressure due to the presence of a pelvic mass and menstrual irregularities. Diagnostic work-up should include pelvic ultrasound, abdomino-pelvic computed tomography (CT scan), chest X-ray and PET scan for selected cases. In young patients serum human chrorionic gonadotropin (hCG), a-fetoprotein (AFP) titer and lactate dehydrogenase (LDH), a complete blood count, and liver and renal function tests should be determined. Inhibin is secreted by granulosa cell tumors and is a useful marker for the disease. In case of suspected gonadoblastomas a preoperative karyotype should be obtained on all pre-menarche girls because of the propensity of these tumors to arise in dysgenetic gonads.
The definitive diagnosis of non-epithelial ovarian cancer requires a surgical specimen. Pathological diagnosis should be made by a gynaecologic pathologist trained in ovarian cancer, according to the World Health Organization classification.
The histologic subtypes are listed in Tables 1 and 2 .
staging and risk assessment
The staging system for non-epithelial ovarian cancers is generally adopted from that used for epithelial ovarian cancer as originally defined by the Fédération Unilateral salpingo-oophorectomy with preservation of the contralateral ovary and the uterus is now considered adequate surgical treatment for patients with GCTs, even in cases of advanced disease, because of the sensitivity of the tumor to chemotherapy, and no systematic ovarian biopsy need be performed where the contralateral ovary is macroscopically normal. Conservative surgery also seems to be the appropriate approach in young patients with SCSTs at stage I disease. For postmenopausal women and in patients with advanced stage disease or with bilateral ovarian involvement, abdominal hysterectomy and bilateral salpingo-oophorectomy should be performed with careful surgical staging.
Stage is the most important prognostic factor established to date for SCSTs, in fact several article have reported that patients with advanced disease have a significantly poorer survival rate.
For GCTs stage is an important prognostic factor as well, though given their sensitivity to chemotherapy treatment even more advanced stage disease can have a good prognosis. advanced stage disease, FIGO stage IIb-IV germ cell tumors. Patients with advanced stage disease should undergo debulking surgery to remove as much gross tumor as possible, but without major extensive procedures given the high chemosensitivity of these tumors. Platinum-based regimens have been the treatment of choice over the past decade for GCTs, with the BEP regimen becoming the most widely used. The optimal duration of therapy is still under debate, but generally many investigators believe that three cycles of BEP with completely resected disease and four cycles for patients with macroscopic residual disease seem appropriate [III, A]. Even though dysgerminomas are very sensitive to radiation therapy there is no evidence to support the use of adjuvant radiation therapy for advanced stage GCTs.
sex cord stromal tumors. Debulking surgery, whenever feasible, remains the most effective treatment for metastatic or recurrent granulosa cell tumors. Platinum-based chemotherapy is currently used for patients with advanced stage SCSTs or recurrent disease, with an overall response rate of 63-80%. There are limited data regarding the utility of chemotherapy in patients with persistent Sertoli-Leydig tumor, but responses in patients with measurable disease have been reported. The BEP regimen for 3-6 cycles is currently recommended for adjuvant postoperative chemotherapy and for patients with recurrent SCSTs. Taxanes demonstrated an interesting activity in SCSTs with a favorable toxicity profile [III, A]. Taxane and platinum combination chemotherapy seems to be a reasonable candidate for future trials. Little evidence exists for the use of hormonal therapy or radiation therapy and these modalities should be restricted to selected cases.
response evaluation
Serum tumor markers (hCG, AFP, LDH, CA125 and inhibin) can accurately correlate with tumor response during chemotherapy. CT scan of the abdomen, pelvis and chest (in case of suspected lung metastases) and pelvic ultrasound are the most common and useful imaging methods to evaluate the response to chemotherapy in patients with measurable disease.
follow-up
Approximately 75% of GCT recurrences occur within the first year after initial treatment; the most common site is the peritoneal cavity and more rarely the retroperitoneal lymph nodes.
In contrast, the indolent nature of SCSTs with a tendency to late recurrence (median time to relapse is 4-6 years), requires long-term surveillance. Several reports describe relapses occurring >20 years (up to 37 years) after diagnosis. Common sites of recurrence are the upper abdomen (55-70%) and the pelvis (30-45%).
The follow-up visit must include history, physical examination with pelvic examination and tumor markers every 3 months for the first 2 years, and every 6 months during years 3-5 or until progression is documented. Pelvic ultrasound should be performed every 6 months in those patients who 
